- Vaccine maker CanSino Biologics Inc. ( OTCPK:CASBF ) added ~76% on Wednesday after the company announced that more Chinese cities follow Shanghai in deploying its inhaled COVID-19 vaccine.
- The Tianjin-based company said in its official social media account that 13 Chinese cities in Jiangsu province, including Wuxi, Huai'an, and Yangzhou, are on track to roll out the vector-based non-invasive vaccine option.
- Hopes of a potential improvement in vaccination rates also led to the rally amid speculation that China was considering a gradual reopening of the country.
- CanSino ( OTCPK:CASBF ) shares in Hong Kong closed ~63% higher on the news, while rival COVID-19 vaccine makers Shanghai Fosun Pharmaceutical Group Co Ltd. ( OTCPK:SFOSF ) and Shanghai Junshi Biosciences Co Ltd. ( OTCPK:SHJBF ) also gained.
- In September, CanSino ( OTCPK:CASBF ) announced that regulators in China authorized its inhaled COVID-19 vaccine Convidecia Air as a booster dose.
For further details see:
CanSino rallies 76% on the promise of inhaled COVID-19 vaccine